151 related articles for article (PubMed ID: 38665954)
1. Impact of neoadjuvant relugolix on patient-reported sexual function and bother.
Hsueh JY; Gallagher L; Koh MJ; Eden S; Shah S; Wells M; Danner M; Zwart A; Ayoob M; Kumar D; Leger P; Dawson NA; Suy S; Rubin R; Collins SP
Front Oncol; 2024; 14():1377103. PubMed ID: 38665954
[TBL] [Abstract][Full Text] [Related]
2. Early biochemical outcomes following neoadjuvant/adjuvant relugolix with stereotactic body radiation therapy for intermediate to high risk prostate cancer.
Gallagher L; Xiao J; Hsueh J; Shah S; Danner M; Zwart A; Ayoob M; Yung T; Simpson T; Fallick M; Kumar D; Leger P; Dawson NA; Suy S; Collins SP
Front Oncol; 2023; 13():1289249. PubMed ID: 37916156
[TBL] [Abstract][Full Text] [Related]
3. Potency preservation following stereotactic body radiation therapy for prostate cancer.
Obayomi-Davies O; Chen LN; Bhagat A; Wright HC; Uhm S; Kim JS; Yung TM; Lei S; Batipps GP; Pahira J; McGeagh KG; Collins BT; Kowalczyk K; Bandi G; Kumar D; Suy S; Dritschilo A; Lynch JH; Collins SP
Radiat Oncol; 2013 Nov; 8():256. PubMed ID: 24180317
[TBL] [Abstract][Full Text] [Related]
4. Testosterone as a Biomarker for Quality of Life (QOL) Following Androgen Deprivation Therapy (ADT) and Stereotactic Body Radiotherapy (SBRT).
Shah S; Pepin A; Forsthoefel M; Burlile J; Collins BT; Simeng S; Aghdam N; Collins S
Cureus; 2023 Aug; 15(8):e44440. PubMed ID: 37791195
[TBL] [Abstract][Full Text] [Related]
5. Bothersome Hot Flashes Following Neoadjuvant Androgen Deprivation Therapy and Stereotactic Body Radiotherapy for Localized Prostate Cancer.
Shah S; Pepin A; Jatar S; Hsueh J; Gallagher L; Danner MT; Zwart A; Ayoob M; Yung TM; Kumar D; Aghdam N; Leger PD; Dawson NA; Simeng S; Collins SP
Cureus; 2024 Mar; 16(3):e55729. PubMed ID: 38586683
[TBL] [Abstract][Full Text] [Related]
6. The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 Trial.
Dearnaley DP; Saltzstein DR; Sylvester JE; Karsh L; Mehlhaff BA; Pieczonka C; Bailen JL; Shi H; Ye Z; Faessel HM; Lin H; Zhu Y; Saad F; MacLean DB; Shore ND
Eur Urol; 2020 Aug; 78(2):184-192. PubMed ID: 32273183
[TBL] [Abstract][Full Text] [Related]
7. Patient-reported outcomes following stereotactic body radiation therapy for clinically localized prostate cancer.
Bhattasali O; Chen LN; Woo J; Park JW; Kim JS; Moures R; Yung T; Lei S; Collins BT; Kowalczyk K; Suy S; Dritschilo A; Lynch JH; Collins SP
Radiat Oncol; 2014 Feb; 9():52. PubMed ID: 24512837
[TBL] [Abstract][Full Text] [Related]
8. Relugolix: A Review in Advanced Prostate Cancer.
Shirley M
Target Oncol; 2023 Mar; 18(2):295-302. PubMed ID: 36652173
[TBL] [Abstract][Full Text] [Related]
9. The Impact of Obesity on Patient Reported Outcomes Following Stereotactic Body Radiation Therapy for Prostate Cancer.
Koneru H; Cyr R; Feng LR; Bae E; Danner MT; Ayoob M; Yung TM; Lei S; Collins BT; Saligan L; Simeng S; Kumar D; Collins SP
Cureus; 2016 Jul; 8(7):e669. PubMed ID: 27551649
[TBL] [Abstract][Full Text] [Related]
10. Relugolix: a novel androgen deprivation therapy for management of patients with advanced prostate cancer.
Saad F; Shore ND
Ther Adv Med Oncol; 2021; 13():1758835921998586. PubMed ID: 34408793
[TBL] [Abstract][Full Text] [Related]
11. Coadministration of Apalutamide and Relugolix in Patients with Localized Prostate Cancer at High Risk for Metastases.
Brown G; Belkoff L; Hafron JM; Saltzstein DR; Potdar R; Bhaumik A; Phillips J; McGowan T; Shore ND
Target Oncol; 2023 Jan; 18(1):95-103. PubMed ID: 36472728
[TBL] [Abstract][Full Text] [Related]
12. An Expert Review on the Combination of Relugolix With Definitive Radiation Therapy for Prostate Cancer.
Roy S; Zaorsky NG; Bagshaw HP; Berlin A; Tree A; Turner S; Koontz B; Nguyen P; Chen R; Dess RT; Jackson WC; Kishan AU; Stish B; Nagar H; Posadas E; Tran PT; Solanki A; Shore ND; Guo G; Ponsky L; Shoag JE; Morgans AK; Garcia JA; Showalter TN; Feng FY; Spratt DE
Int J Radiat Oncol Biol Phys; 2022 Jun; 113(2):278-289. PubMed ID: 34923058
[TBL] [Abstract][Full Text] [Related]
13. Impact of Age on Patient-Reported Outcomes Following Stereotactic Body Radiation Therapy for Prostate Cancer.
Pepin A; Pernia M; Danner MT; Ayoob M; Yung TM; Lei S; Collins BT; Simeng S; Aghdam N; Collins SP
Cureus; 2021 Mar; 13(3):e13780. PubMed ID: 33842156
[TBL] [Abstract][Full Text] [Related]
14. Ejaculatory Function Following Stereotactic Body Radiation Therapy for Prostate Cancer.
Sholklapper T; Creswell M; Cantalino J; Markel M; Zwart A; Danner M; Ayoob M; Yung T; Collins B; Kumar D; Aghdam N; Rubin RS; Hankins R; Suy S; Collins S
J Sex Med; 2022 May; 19(5):771-780. PubMed ID: 35305936
[TBL] [Abstract][Full Text] [Related]
15. Sexual bother in men with advanced prostate cancer undergoing androgen deprivation therapy.
Benedict C; Traeger L; Dahn JR; Antoni M; Zhou ES; Bustillo N; Penedo FJ
J Sex Med; 2014 Oct; 11(10):2571-80. PubMed ID: 25059094
[TBL] [Abstract][Full Text] [Related]
16. Erectile function after stereotactic body radiotherapy for localized prostate cancer.
Dess RT; Hartman HE; Aghdam N; Jackson WC; Soni PD; Abugharib AE; Suy S; Desai NB; Zumsteg ZS; Mehra R; Morgan TM; Feng FY; Hamstra DA; Schipper MJ; Collins SP; Spratt DE
BJU Int; 2018 Jan; 121(1):61-68. PubMed ID: 28710895
[TBL] [Abstract][Full Text] [Related]
17. Relugolix, an oral gonadotropin-releasing hormone antagonist for the treatment of prostate cancer.
George DJ; Dearnaley DP
Future Oncol; 2021 Nov; 17(33):4431-4446. PubMed ID: 34409852
[TBL] [Abstract][Full Text] [Related]
18. Impact of Concomitant Prostate Cancer Medications on Efficacy and Safety of Relugolix Versus Leuprolide in Men With Advanced Prostate Cancer.
George DJ; Saad F; Cookson MS; Saltzstein DR; Tutrone R; Bossi A; Brown B; Selby B; Lu S; Buckley D; Tombal B; Shore ND
Clin Genitourin Cancer; 2023 Jun; 21(3):383-392.e2. PubMed ID: 37062659
[TBL] [Abstract][Full Text] [Related]
19. Evaluating relugolix for the treatment of prostate cancer in real-world settings of care: the OPTYX study protocol.
Spratt DE; Dorff T; McKay RR; Lowentritt BH; Fallick M; Gatoulis SC; Flanders SC; Ross AE
Future Oncol; 2024 Apr; 20(12):727-738. PubMed ID: 38488039
[TBL] [Abstract][Full Text] [Related]
20. Effect of androgen deprivation therapy on sexual function and bother in men with prostate cancer: A controlled comparison.
Donovan KA; Gonzalez BD; Nelson AM; Fishman MN; Zachariah B; Jacobsen PB
Psychooncology; 2018 Jan; 27(1):316-324. PubMed ID: 28557112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
